Filter your search
- $995.00 – $5,990.00With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will […]January 1, 2006$3,000.00 – $6,000.00The U.S. Market for OTC anti-infective products surpassed the $2 billion mark last year. Although overall growth is sluggish, the market is a proven revenue source for a number of major brands, and there have been some nice surprises in the performance of some categories, such as first-aid related antiseptic and antibiotic products. This comprehensive […]January 1, 2006$3,500.00 – $7,000.00The U.S. long-term care industry experienced strong growth from 1999 through 2004 and this growth is expected to continue through the end of the decade. Indeed, the aging of the U.S. population will push unprecedented demand for all forms of long-term care, but ongoing cost containment issues continue to pressure both private and public managed […]January 1, 2006$2,995.00 – $5,990.00In the Spring of 2003, Kalorama published its first report on Outsourcing in Drug Discovery. Since then, so much has changed, the use of the term “2nd Edition” hardly seems appropriate. This new study involved completely re-examining the market from the ground up. This new report is designed to make readers aware of the enormous […]January 1, 2006$2,500.00 – $7,000.00This completely updated 2nd edition to Kalorama’s popular 2003 study focuses on the market applications of current and advanced drug delivery technology to the development of new and modified pharmaceutical products in the United States. Taking a strategic view of the various therapeutic areas on which drug delivery is anticipated to have its greatest impact, […]November 15, 2005$3,500.00 – $7,000.00Although, the next 15-20 years will shift a majority of the population into the elderly population group, children will continue to remain the bulk of the dependent population worldwide with 9 in every 10 people falling into a pediatric age range in the less developed regions of Africa, Asia and Latin America. Therefore, the treatment […]November 1, 2005$2,500.00 – $5,000.00Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% […]November 1, 2005$4,995.00 – $9,990.00There has not been a year in the last decade in which the IVD market in China has failed to grow. With a gross domestic product of over $1.4 trillion, China surpassed Italy last year to become the world’s sixth largest economy, according to the International Monetary Fund. This country of 1.3 billion people is […]November 1, 2005$3,500.00 – $7,000.00Respiratory diseases are among the most common ailments across the world. Asthma and chronic obstructive pulmonary disease (COPD) are the major causes of mortality rates among children and elderly. Currently, about 300 million people suffer from asthma—the number only expected to rise over next few years—and about 14.2 million people suffer from COPD. Given these […]November 1, 2005$3,500.00 – $7,000.00Cancer, with its high prevalence and mortality rate, continues to rank among the world’s deadliest and most costly diseases. According to the WHO, in 2003, about 25 million people live with cancer and nearly 11 million new cases are diagnosed each year. With advances in protein and cell chemistry, genetics and molecular biology researchers are […]October 1, 2005